Use of Fish Skin Graft (FSG) to Improve Wound Healing and Expedite Discharge at a County Safety-net Hospital
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Mar 27, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment using fish skin grafts (FSG) to help heal large surgical wounds and potentially allow patients to leave the hospital sooner. The study will involve adult patients who have a surgical wound that is at least 40 square centimeters and needs a special cleaning procedure called surgical debridement.
To participate, patients should be between 65 and 74 years old, have a wound that meets the size requirement, and be willing to follow up for up to a year after treatment. However, those with wounds that don’t need surgery, allergies to fish, or who may have trouble following up (like those living out of state or in police custody) won’t be eligible. Participants can expect close monitoring and support throughout the trial to help assess how well the fish skin graft works for their healing process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Has wound greater than or equal to 40cm2 requiring surgical debridement
- • Agreeable to follow up period of up to 1 year
- Exclusion Criteria:
- • Patients with wounds that do not require surgical debridement.
- • Patients with a known allergy or other sensitivity to fish material
- • Patients who are deemed unlikely to follow up (e.g., patients who live out of state).
- • Patients in police custody/incarcerated.
- • Patients unable to communicate in either Spanish or English.
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Jonah Stulberg, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported